Brick & Kyle Associates bought a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 25,450 shares of the medical equipment provider’s stock, valued at approximately $2,980,000. Zimmer Biomet Holdings makes up approximately 2.4% of Brick & Kyle Associates’ portfolio, making the stock its 14th biggest position.

Several other institutional investors have also made changes to their positions in ZBH. JPMorgan Chase & Co. raised its holdings in shares of Zimmer Biomet Holdings by 92.7% during the second quarter. JPMorgan Chase & Co. now owns 3,279,951 shares of the medical equipment provider’s stock valued at $421,146,000 after acquiring an additional 1,577,874 shares in the last quarter. Harbour Capital Advisors LLC raised its holdings in Zimmer Biomet Holdings by 13,131.3% in the second quarter. Harbour Capital Advisors LLC now owns 1,302,618 shares of the medical equipment provider’s stock worth $10,145,000 after purchasing an additional 1,292,773 shares in the last quarter. Longview Partners Guernsey LTD raised its holdings in Zimmer Biomet Holdings by 17.7% in the third quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock worth $878,958,000 after purchasing an additional 1,128,973 shares in the last quarter. Koch Industries Inc. raised its holdings in Zimmer Biomet Holdings by 49,697.3% in the second quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock worth $1,033,000 after purchasing an additional 1,038,674 shares in the last quarter. Finally, BlackRock Inc. raised its holdings in Zimmer Biomet Holdings by 4.1% in the second quarter. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider’s stock worth $2,236,657,000 after purchasing an additional 679,080 shares in the last quarter. Institutional investors own 85.36% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Brick & Kyle Associates Invests $2.98 Million in Zimmer Biomet Holdings, Inc. (ZBH)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/11/20/brick-kyle-associates-invests-2-98-million-in-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Holdings, Inc. (ZBH) traded down $0.63 during trading on Monday, hitting $111.61. The company had a trading volume of 1,043,200 shares, compared to its average volume of 1,364,669. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.78. Zimmer Biomet Holdings, Inc. has a 12 month low of $98.20 and a 12 month high of $133.49. The stock has a market capitalization of $22,640.00, a PE ratio of 13.83, a PEG ratio of 1.73 and a beta of 1.17.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.02). Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. The business had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.83 billion. During the same period last year, the business earned $1.79 earnings per share. The company’s quarterly revenue was down .8% on a year-over-year basis. research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.03 earnings per share for the current fiscal year.

ZBH has been the subject of a number of research reports. Zacks Investment Research downgraded Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. BidaskClub downgraded Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a report on Monday, July 24th. SunTrust Banks, Inc. set a $136.00 price objective on Zimmer Biomet Holdings and gave the stock a “buy” rating in a report on Wednesday, November 1st. Canaccord Genuity downgraded Zimmer Biomet Holdings from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $141.00 to $135.00 in a report on Friday, July 28th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $135.00 price objective on shares of Zimmer Biomet Holdings in a report on Friday, July 28th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $133.71.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.